World's Best Scientists 2026 revealed!
Ian F. Tannock

Ian F. Tannock

D-Index & Metrics

Medicine

D-Index
131
Citations
81127
World Ranking
2359
National Ranking
91

Ian F. Tannock publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ian F. Tannock sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 646 publications — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ian F. Tannock D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ian F. Tannock sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 131 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ian F. Tannock is affiliated with the University of Toronto in Canada. Their primary research focus lies within the field of Medicine, with significant contributions in several subfields including Pulmonary and Respiratory Medicine, Economics and Econometrics, Oncology, Cancer Research, and Statistics and Probability.

The scientist's main research topics encompass Cancer Genomics and Diagnostics, Health Systems, Economic Evaluations, Quality of Life, Statistical Methods in Clinical Trials, Economic and Financial Impacts of Cancer, Prostate Cancer Treatment and Research, Lung Cancer Treatments and Mutations, and Prostate Cancer Diagnosis and Treatment.

Their recent published papers include:

  • The Lancet Commission on prostate cancer: planning for the surge in cases (2024, The Lancet)
  • Priorities for cancer research in low- and middle-income countries: a global perspective (2022, Nature Medicine)
  • Informative censoring - a neglected cause of bias in oncology trials (2020, Nature Reviews Clinical Oncology)
  • Common Sense Oncology: outcomes that matter (2023, The Lancet Oncology)
  • Informing Patients About Expected Outcomes: The Efficacy-Effectiveness Gap (2020, Journal of Clinical Oncology)

Frequent co-authors collaborating with Ian F. Tannock include:

  • Christopher M. Booth
  • Daniel A. Goldstein
  • Bishal Gyawali
  • Elizabeth A. Eisenhauer
  • Dario Trapani

The scholar has published extensively in prominent venues, notably:

  • The Lancet Oncology (12 publications)
  • Journal of Clinical Oncology (10 publications)
  • Annals of Oncology (10 publications)
  • JAMA Oncology (4 publications)
  • Nature Reviews Clinical Oncology (3 publications)

Best Publications

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

  • Drug penetration in solid tumours

    Andrew I. Minchinton;Ian F. Tannock

  • Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

    Arnoud J. Templeton;Mairéad G. McNamara;Boštjan Šeruga;Francisco E. Vera-Badillo

  • Drug Resistance and the Solid Tumor Microenvironment

    Olivier Trédan;Carlos M Galmarini;Krupa Patel;Ian F Tannock

  • Acid pH in Tumors and Its Potential for Therapeutic Exploitation

    Ian F. Tannock;Daniela Rotin

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

    I. F. Tannock;D. Osoba;M. R. Stockler;D. S. Ernst

  • Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

    Camilla Zimmermann;Nadia Swami;Monika Krzyzanowska;Monika Krzyzanowska;Breffni Hannon;Breffni Hannon

  • Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

    Dominik R. Berthold;Gregory R. Pond;Freidele Soban;Ronald de Wit

  • A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    Fadlo R. Khuri;John Nemunaitis;Ian Ganly;James Arseneau

  • A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    P J Loehrer;L H Einhorn;P J Elson;E D Crawford

  • The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour.

    I F Tannock

  • Delivering affordable cancer care in high-income countries

    Richard Sullivan;Jeffrey Peppercorn;Karol Sikora;John Zalcberg

  • Cytokines and their relationship to the symptoms and outcome of cancer.

    Bostjan Seruga;Haibo Zhang;Lori J. Bernstein;Ian F. Tannock

  • Repopulation of cancer cells during therapy: an important cause of treatment failure

    John J. Kim;Ian F. Tannock

  • Cognitive function in breast cancer patients receiving adjuvant chemotherapy.

    Christine B. Brezden;Kelly-Anne Phillips;Mohamed Abdolell;Terry Bunston

  • Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

    S B Saxman;K J Propert;L H Einhorn;E D Crawford

  • Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial

    M. K B Parmar;M. Adams;M. Balestrino;K. Bertelsen

  • Prognostic Role of Platelet to Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis

    Arnoud J. Templeton;Olga Ace;Mairéad G. McNamara;Mustafa Al-Mubarak

  • Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.

    Ian F Tannock;Carol M Lee;Jonathon K Tunggal;David S M Cowan

Frequent Co-Authors

Gregory R. Pond
Gregory R. Pond McMaster University
George Tomlinson
George Tomlinson University of Toronto
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Padraig Warde
Padraig Warde Princess Margaret Cancer Centre
Neil Fleshner
Neil Fleshner Princess Margaret Cancer Centre
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Malcolm J. Moore
Malcolm J. Moore Princess Margaret Cancer Centre
Susan Halabi
Susan Halabi Duke University
Pamela J. Goodwin
Pamela J. Goodwin University of Toronto
Gordon Winocur
Gordon Winocur University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn't always mean following the traditional medical school path. Numerous accredited online programs offer flexible, accessible routes into healthcare fields. For registered nurses looking to advance their credentials quickly, adn to np programs online allow professionals to bridge from an Associate Degree in Nursing to a Nurse Practitioner role, often while continuing to work.

Those interested in health and wellness can pursue an online nutrition degree to build expertise in food science, dietetics, and preventive healthcare—key areas as public interest in nutrition surges.

For aspiring leaders, top online mha programs that are cahme accredited provide rigorous training in healthcare administration, preparing graduates to manage hospitals and healthcare systems with cutting-edge skills.

Additionally, online rn to bsn programs no clinicals support nurses in upgrading their qualifications without the challenge of on-site clinical requirements, streamlining career growth for busy professionals.

Each of these online degrees opens doors to rewarding roles in healthcare, tailored for students seeking flexible study options and diverse career pathways.

Best Scientists Citing Ian F. Tannock

Trending Scientists

Recently Published Articles